Clinical Study of Recombinant Novel Coronavirus Vaccine

Summary

Clinical Study of Recombinant Novel Coronavirus Vaccine is a clinical trial^[1].

Key Facts

• Clinical Study of Recombinant Novel Coronavirus Vaccine's instance of is recorded as clinical trial^[2].
• Clinical Study of Recombinant Novel Coronavirus Vaccine's start time is recorded as +2020-07-12T00:00:00Z^[3].
• Clinical Study of Recombinant Novel Coronavirus Vaccine's end time is recorded as +2021-09-15T00:00:00Z^[4].
• Clinical Study of Recombinant Novel Coronavirus Vaccine's number of participants is recorded as {'unit': '1', 'amount': '+900'}^[5].
• Clinical Study of Recombinant Novel Coronavirus Vaccine's title is recorded as A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years^[6].
• Clinical Study of Recombinant Novel Coronavirus Vaccine's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[7].
• Clinical Study of Recombinant Novel Coronavirus Vaccine's ClinicalTrials.gov ID is recorded as NCT04466085^[8].
• Clinical Study of Recombinant Novel Coronavirus Vaccine's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+59'}^[9].
• Clinical Study of Recombinant Novel Coronavirus Vaccine's clinical trial phase is recorded as phase II clinical trial^[10].
• Clinical Study of Recombinant Novel Coronavirus Vaccine's research site is recorded as government of the People's Republic of China^[11].
• Clinical Study of Recombinant Novel Coronavirus Vaccine's research subject recruitment status is recorded as recruiting^[12].
• Clinical Study of Recombinant Novel Coronavirus Vaccine's study type is recorded as interventional study^[13].